本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneSEQ-WY01*. With potential across different areas of genomics, CycloneSEQ™ technology integrates numerous technological improvements, including advanced protein engineering, a novel flow cell design, and a cutting-edge basecalling algorithm, to enable high accuracy and throughput in sequencing. Left: CycloneSEQ-WT02, Right: CycloneSEQ-WY01 "By integrating CycloneSEQ™ nanopore sequencing with our proprietary DNBSEQ™ sequencing technology, we are excited to further expand our omics technologies portfolio." said Duncan Yu, President of MGI. "This advancement allows us to provide MGI partners and customers worldwide with a full suite of omics capabilities across diverse range of sequencing throughputs and read lengths, single-cell sequencing, and spatial omics. With this, MGI solidifies its position as a life science technology provider to offer the most extensive multi-omics solutions available today." Advanced features facilitate high-throughput, long-read sequencing Leveraging its robust design improvements, CycloneSEQ™ has demonstrated competitive advantages in sequencing performance, bringing further flexibility and diversity to MGI's comprehensive range of life science research tools. Enhanced motor and nanopore protein performance. In an analysis of deep-sea metagenomic datasets collected from extreme environments, researchers discovered an abundance of proteins associated with genetic manipulation, showcasing significant structural diversity. Notably, a motor protein with high thermal stability, excels at unwinding nucleic acids, while a nanopore protein offers structural rigidity, low sequencing noise, and high signal quality due to its small pore diameter. Building on these novel structural features, CycloneSEQ™ leverages enhanced nucleic acid capture capabilities, enabling more efficient DNA threading. This improvement significantly boosts the platform's overall sequencing efficiency and reliability. Improved flow cell design. A single flow cell houses up to 4,096 nanopore protein sensors in a high-density array, optimized for ultra-low sequencing noise. Maximizing the expansion of microwell volume facilitates ultra-long sequencing times. The integration of BioMEMS and ASIC enables precise detection of picoampere-level currents, ensuring real-time, stable nucleic acid sequencing. Optimized basecalling algorithm. CycloneSEQ™ has independently developed a basecalling algorithm model. This algorithm model, based on extensive data and large-scale distributed training, achieves a high accuracy rate of 97% and is capable of real-time sequencing decoding for multiple flow cells, demonstrating robust performance. Innovative chemistry. CycloneSEQ™ has developed a novel sequencing chemistry, named nanopore local chemistry (NLC). By controlling the electrophoretic migration of Magnesium ions, Mg ions are pumped in to the Cis chamber and locally bounded to the ATP molecules. Subsequently, ATP-Mg is activated, thereby controlling the activity of the motor protein. CycloneSEQ products empower diverse genomic applications Based on this state-of-the-art technology, the new launched CycloneSEQ-WT02 and CycloneSEQ-WY01 sequencers have achieved significant breakthrough in throughput, accuracy, applications and flow cell design by building an optimal combination of patterns, demonstrating great potential in a variety of applications, including public health, genetic screening, reproductive health, environmental research, cancer research, genomics education, agri-genomics research and epigenomics research, etc. CycloneSEQ-WT02 nanopore gene sequencer features a dual flow cell architecture, allowing for simultaneous independent operation. With the capacity to support fast coverage, swift sequencing, flexible testing and real-time analysis, CycloneSEQ-WT02 significantly shorten sequencing turnaround time, effectively overcoming the challenges of complex sequences. It has been successfully applied in a variety of scenarios, including the detection of complex genetic diseases such as thalassemia, generating telomere-to-telomere (T2T) genome maps for small animals, deep-sea in situ exploration, rapid identification of clinical respiratory pathogens, and de novo genome assembly. CycloneSEQ-WY01 is a high-throughput nanopore gene sequencer. It features a high-density flow cell and ultra-high throughput capabilities, enabling ultra-long read lengths, real-time sequencing, and continuous testing. In terms of performance parameters, both sequencers offer read lengths ranging from bp to Mbp, accommodating a wide range of applications from basic research to complex disease studies. Sequencing can be completed within 10 minutes to 72 hours, depending on experimental needs, with an average speed of 350–420 nt/s. The single time accuracy is 97% and the consensus accuracy is 99.99% (40x). Results are delivered in real-time, ensuring a short detection cycle and reduced sequencing costs. The CycloneSEQ-WT02 features up to 4,096 nanopore proteins per flow cell, with a maximum single-flow cell throughput of 50 Gb and up to 100 Gb for the dual flow cell system in real laboratory experiments. The CycloneSEQ-WY01, with over 30,000 nanopores proteins per flow cell, significantly enhances sequencing throughput and data output rate, helping users shorten sequencing cycles and improve efficiency. CycloneSEQ-WT02 sequencer will be open for order in select countries later this year through MGI's commercial channel, and CycloneSEQ-WY01 is slated for available in H1, 2025. With the latest sequencers added to robust lineup, MGI is now equipped to deliver a full-spectrum of sequencing technologies and a comprehensive product portfolio. This expansion fully embodies MGI's "SEQ ALL" approach, a term showcasing its capability in providing global users with a comprehensive toolkit for multi-omics research across various throughput, read length and applications. For more information, please visit: https://en.mgitech.cn/Home/Products/instruments_info/id/65.html About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/ , LinkedIn, X, and YouTube. *For research use only. Not for use in diagnostic procedures
Under the commercial agreement, A. Menarini Diagnostics will assume exclusive marketing of the non-invasive Bladder EpiCheck® test in Europe in the months ahead, providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). FLORENCE, Italy, Sept. 9, 2024 /PRNewswire/ -- A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced at the 36th European Congress of Pathology in Florence, that they have entered into a long-term commercial agreement for the exclusive distribution of the Bladder EpiCheck® test in Europe. This non-invasive CE-marked test detects primary or recurrent bladder cancer and upper tract urinary cancer. Bladder EpiCheck is included in the European Association of Urology (EAU) Clinical Guidelines as a urine test that might be used in the initial diagnostic workup of bladder cancer to avoid / implement cystoscopy and in follow-up to monitor for non-muscle invasive bladder cancer (NMIBC) tumor recurrence to replace or postpone cystoscopy. The test is also included in the EAU Clinical Guidelines as an ancillary tool in the diagnosis and monitoring of UTUC. Bladder cancer is the sixth most common cancer[1] as there are approximately 760,000 people in Europe living with the disease[2]. Surveillance is of paramount importance for NMIBC patients due to the high rates of recurrence and risk of progression to life-threatening disease. For high-risk NMIBC patients, follow up can be as frequent as every three months and requires invasive cystoscopies. By providing a non-invasive, monitoring test, Bladder EpiCheck could detect high-grade disease early and potentially reduce the frequency of cystoscopies, which may, in turn, decrease the burden of bladder cancer surveillance for patients and health systems alike while improving patient outcome by identifying the patients who will benefit most from intervention. "I am pleased to be working with A. Menarini Diagnostics to further build the Bladder EpiCheck market in Europe," commented Chris Hibberd, Executive Chairman & CEO of Nucleix. "Given the broad presence of A. Menarini Diagnostics, we believe they are the right partner to expand the market footprint for our liquid biopsy test that we believe will transform bladder cancer care by supporting doctors in optimizing decision-making for the benefit of patients." "With this agreement, we are expanding our portfolio by providing patients in Europe a non-invasive alternative for detecting primary and recurrent bladder cancer through a simple urine test," said Fabio Piazzalunga, General Manager and Global Head of Menarini Diagnostics. "This strategic agreement is a significant testament to the company's position as a preferred partner for promoting and bringing highly innovative diagnostic solutions to market." The alliance between A. Menarini Diagnostics and Nucleix aims to accelerate the adoption of the Bladder EpiCheck® for the benefit of European patients and transform bladder cancer patients' care. About Nucleix® Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company's pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company's non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals, while evaluating additional tests for other high-risk diseases. For more information, please visit: https://www.nucleix.com. About A. Menarini Diagnostics A. Menarini Diagnostics brings advanced solutions to the In Vitro Diagnostics (IVD) market and develops innovative systems and reagents to provide healthcare professionals with reliable information to meet their diagnostics needs. For more than 45 years, the Company has been dedicated to helping healthcare professionals make safe and sustainable diagnoses, improving the quality of life of people all over the world. A. Menarini Diagnostics is part of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries. For more information, please visit: https://www.menarinidiagnostics.com/en-us/ [1] Cancer TODAY | IARC - https://gco.iarc.who.int Data version: Globocan 2022 (version 1.1) - 08.02.2024 [2] Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today, accessed [06 August 2024]. Contact: PAVY Consulting, Linda PAVY, lipavy@pavyconsulting.com
ANYANG-SI, South Korea, Sept. 6, 2024 /PRNewswire/ -- Vieworks, a leading name in bioimaging solutions, is to set a new standard in the digital pathology field with the launch of its high-speed slide scanner LUCEON 510. Vieworks will be making its debut as a digital pathology solution provider at the upcoming European Congress of Pathology (ECP) 2024, one of the most prestigious events in the digital pathology community, in Florence, Italy (Booth 39, September 7th – 10th). Digital pathology slide scanner LUCEON 510 Employing the intricately designed 3-camera structure, LUCEON delivers four different imaging modes each optimized for varying applications, including histopathology slides, liquid-based cytology slides, and cytology slides. Three Vieworks cameras—developed and manufactured entirely by Vieworks—obtain three differently focused images at once with scan time and data size comparable to that of a single camera. Among the four imaging modes, the tri-focal layer merge mode captures and fuses three individual images real-time, resulting in a single fusion image containing the best focused pixels from each image. A variation of the conventional Z-stack, the tri-focal layer merge Z-stack mode utilizes LUCEON's 3-camera structure to acquire images with a scan time 3 times faster and image size one-third of Z-stack. LUCEON 510 loads up to 510 slides when fully loaded with 17 racks, 30 slides per rack. Vieworks' patent pending compatibility adapter allows the use of both 30 slide racks and 20 slide racks. With a scan speed of 30 seconds per slide, LUCEON scans up to 83 slides per hour (15 mm x 15 mm, 40x). Four Imaging Modes 1. Best focused layer mode- Automatically selects image with best image quality- Histopathology slides 2. Tri-focal layer merge mode- Three individual images are captured and fused real-time- Resulting fusion image contains best focused pixels from each individual image- Liquid-based cytology slides 3. Z-stack mode- High speed Z-stack- Adjusts layer spacing in increments of 0.1 ㎛- Cytology slides 4. Tri-focal layer merge Z-stack- High speed tri-focal layer merge Z-stack- Adjusts layer spacing in increments of 0.1 ㎛ (recommended spacing: 1 ㎛)- Cytology slides About Vieworks Co., Ltd. As a global leader in digital imaging in various applications from bioimaging, medical X-ray imaging to machine vision, Vieworks offers the most advanced imaging solutions to digital pathology. Vieworks creates new standards in bioimaging industry by providing research professionals with the most valued and high-quality images and offering innovative vision and insight for all. For more information, please visit bioimaging.vieworks.com.
FORT MILL, S.C., Sept. 6, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced that Baird Medical Investment Holdings Limited's ("PubCo") registration statement on Form F-4 (the "Registration Statement") related to their previously announced proposed business combination (the "Business Combination") has been declared effective by the U.S. Securities and Exchange Commission (the "SEC"). The declaration of effectiveness of the Registration Statement by the SEC and ExcelFin's filing of the definitive proxy statement/prospectus is an important step in Baird Medical becoming a publicly-traded company listed on the Nasdaq upon the close of the Business Combination. ExcelFin has scheduled the Special Meeting of Stockholders (the "Special Meeting") to approve the proposed business combination with Baird Medical to be held on September 26, 2024. The Business Combination is expected to close shortly after approval by ExcelFin's stockholders and the satisfaction of other customary closing conditions as described in the definitive proxy statement/prospectus. A copy of the definitive proxy statement/prospectus can be accessed via the SEC website at www.sec.gov. Additional Information and Where to Find It On June 26, 2023, ExcelFin, Betters Medical, PubCo, Betters Medical Merger Sub, Inc., Betters Medical Merger Sub 2, Inc., Betters Medical NewCo, LLC and Tycoon Choice Global Limited ("Tycoon"), entered into a Business Combination Agreement as amended from time to time (the "Business Combination Agreement"). In connection with the transactions contemplated by the Business Combination Agreement (the "Transactions"), PubCo has filed with the SEC the Registration Statement (Registration No. 333-274114). The Registration Statement includes both the proxy statement to be distributed to ExcelFin's stockholders in connection with ExcelFin's solicitation of proxies for the vote by ExcelFin's stockholders with respect to the Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of PubCo to be issued in connection with the Business Combination. STOCKHOLDERS OF EXCELFIN ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTIONS THAT PUBCO AND EXCELFIN WILL FILE OR HAVE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS AND THE PARTIES TO THE PROPOSED TRANSACTIONS. Stockholders and investors may obtain free copies of the proxy statement/prospectus and other relevant materials and other documents filed by PubCo and ExcelFin at the SEC's website at www.sec.gov. Copies of the proxy statement/prospectus may also be obtained, without charge, on ExcelFin's website at www.excelfinacquisitioncorp.com or by directing a request to: ExcelFin Acquisition Corp., 100 Kingsley Park Drive, Fort Mill, South Carolina 29715. Participants in Solicitation Each of PubCo, ExcelFin and Baird Medical and their respective directors, executive officers and certain employees may be deemed, under SEC rules, to be participants in the solicitation of proxies in respect of the proposed Transactions. Information regarding the directors and executive officers of PubCo, ExcelFin and Baird Medical and the other participants in the proxy solicitation, and a description of their direct and indirect interests in the proposed Transactions, by security holdings or otherwise, is contained in the Registration Statement and other relevant materials filed with the SEC. These documents can be obtained free of charge from the sources indicated above. Non-Solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Transactions and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of ExcelFin, Baird Medical, PubCo, or Tycoon, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. About Baird Medical Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading microwave ablation ("MWA") medical device manufacturer and provider in China. Baird Medical's proprietary medical devices are used for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung cancer and breast lumps. Baird Medical is the first company to obtain a Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For more information, please visit http://baidesz.com/. About ExcelFin ExcelFin is a blank check company formed as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ExcelFin's sponsors include Grand Fortune Capital, LLC ("GFC") and Fin Venture Capital ("Fin"). GFC is an affiliate of an investment group that completed a series of significant M&A transactions and investments in FinTech, Technology, Media, and Telecommunications ("TMT") and Healthcare. Fin is a private equity firm focused on FinTech software. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or ExcelFin's, Baird Medical's, PubCo's or Tycoon's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by ExcelFin and Baird Medical and their management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. None of PubCo, ExcelFin, or Baird Medical undertakes any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the proposed Transactions, including the risks that (a) the proposed Transactions may not be consummated within the anticipated time period, or at all; (b) ExcelFin may fail to obtain stockholder approval of the proposed Business Combination; (c) the Parties may fail to secure required regulatory approvals under applicable laws; and (d) other conditions to the consummation of the proposed Transactions under the Business Combination Agreement may not be satisfied; (2) the effects that any termination of the Business Combination Agreement may have on ExcelFin or Baird Medical or their respective businesses, including the risk that ExcelFin's share price may decline significantly if the proposed Transactions are not completed; (3) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (4) the effects that the announcement or pendency of the proposed Transactions may have on Baird Medical and its business, including the risk that as a result (a) ExcelFin's business, operating results or stock price may suffer or (b) PubCo's, ExcelFin's or Baird Medical's current plans and operations may be disrupted; (5) the inability to recognize the anticipated benefits of the proposed Transactions; (6) unexpected costs resulting from the proposed Transactions; (7) changes in general economic conditions; (8) regulatory conditions and developments; (9) changes in applicable laws or regulations; (10) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the proposed Transactions and instituted against PubCo, ExcelFin, Baird Medical or others; and (11) other risks and uncertainties from time to time described in the Registration Statement relating to the proposed Transactions, including those listed under the section titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by PubCo in connection with the proposed Transactions. All subsequent written and oral forward-looking statements concerning ExcelFin, Baird Medical, PubCo or Tycoon, the Transactions described herein or other matters attributable to ExcelFin, Baird Medical, PubCo, Tycoon or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Each of ExcelFin, Baird Medical, PubCo and Tycoon expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. ContactsInvestor RelationsRobin Yang, PartnerICR, LLCPhone: +1 (646) 308-1475Email: BairdMedical.IR@icrinc.com Public RelationsBrad Burgess, Senior Vice PresidentICR, LLCPhone: +1 (646) 588-0383Email: BairdMedical.PR@icrinc.com
SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval in China. This groundbreaking achievement is now officially listed on the National Medical Products Administration (NMPA) website (Registration Certificate No.: JXZZ 20242220334) and marks a significant milestone in the field of medical diagnostics. The UD-X™ Single-Molecule Analyzer is designed for the ultra-sensitive detection and quantification of trace protein biomarkers in body fluids, reaching sensitivity levels at the fg/ml scale. This technology will be utilized alongside soon-to-be-approved companion assay kits, addressing the precision detection needs of clinical diagnostics and community health screenings. The successful approval and clinical deployment of the UD-X™ Single-Molecule Analyzer are poised to revolutionize early screening, early diagnosis, companion diagnosis and treatment effectiveness evaluation for diseases such as Alzheimer's Disease (AD). This advancement is not only of immense clinical value but also holds significant social and economic importance. Driven by a passion for innovation and a deep commitment to patient care, UltraDx Bio is dedicated to enhancing its R&D and production capabilities. The company is committed to fostering collaborations with various stakeholders to promote continuous advancements in disease screening, precision diagnostics, and the development of versatile application platforms. Together, we aim to drive the industry's growth and improve global health outcomes. Product Launch Ceremony On August 25, 2024, UltraDx Bio hosted the launch ceremony for the UD-X™ Single-Molecule Analyzer. The event was a significant success, with Jay Zengjun Dong, CEO of UltraDx Bio, delivering an inspiring keynote address. The event garnered widespread attention from both industry insiders and external observers, attracting renowned experts and thought leaders who acknowledged the exceptional performance of the single-molecule array technology in both academic and clinical research. They also expressed high expectations for its future applications in early detection and diagnosis of diseases like Alzheimer's. Jay Dong, CEO of UltraDx Bio Distinguished guests included world-renowned key thought leaders, scientists and clinical experts : Academician George Fu Gao, Member of National Academy of Sciences of USA, Member of Royal Academy, and Member of Chinese Academy of Sciences, and president of Chinese Society of Biotechnology and former Director of China CDC in Beijing; Academician Guoliang Xu , the Member of Chinese Academy of Sciences, a research Professor of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Professor Jintai Yu, of National Clinical Center for Neurological diseases in Shanghai, Deputy Director of Neurology of Huashan Hospital Affiliated to Fudan University, Deputy Director of Neurology Research Institute of Fudan University, and Vice Chairman of Neurology Committee, Chinese Medical Association; Professor Yanning Cai, of National Clinical Center for Neurological diseases in Beijing, Director of the Clinical Sample Center of Xuanwu Hospital of Capital Medical University in Beijing and Deputy Director of the Key Project Department of the National Center for Neurological Diseases, and other clinical experts and scholars toured our company clinical and product facility, inspected the company's production process, quality control system, and the progress of the product research and development, and explored the cutting-edge of the precision medicine testing technology. The experts pointed out that with the aggravation of aging population, the incidence of Alzheimer's disease is increasing year by year, which brings a heavy burden to patients, their families and the society. Strengthening the basic and clinical research and clinical application transformation in this field is one of the important tasks and social responsibilities shared by both the clinical side and the industry side. Subsequently, all invited experts had focused discussion on the topic of "Opportunities and Prospects of Early Detection and early Diagnosis of Diseases", with a focus on AD and cancer, reached a consensus that the low rate of early diagnosis and consultation of diseases represented by Alzheimer's Disease is mainly due to (1) insufficient knowledge of patients about the disease; (2) lack of means of early diagnosis and effective treatment; and (3) the early diagnosis rate is closely related to the development progress of society. 【Expert Opinions】 Academician George Fu Gao, the Member of the Chinese Academy of Sciences, the Foreign Member of the U.S. National Academy of Sciences , the foreign member of the Royal Academy, emphasized that precision diagnosis is the cornerstone of precision medicine, praising UltraDx Bio's efforts in developing advanced diagnostic tools for Alzheimer's disease. Academician George Fu Gao, the Member of the Chinese Academy of Sciences, the Foreign Member of the U.S. National Academy of Sciences , the foreign member of the Royal Academy Academician Guoliang Xu, the Member of the Chinese Academy of Sciences, a researcher at the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, underscored the necessity of in-depth basic research for technological advancement and the translation of scientific findings into clinical and industrial applications. He further emphasized, "The results of scientific research should also rely on clinical and corporate industry translation to ultimately benefit human beings." "we shall also pay more attention to individual variation." Academician Guoliang Xu, the Member of the Chinese Academy of Sciences, a researcher at the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Prof. Jintai Yu, of National Clinical Center for Neurological diseases in Shanghai, Deputy Director of Department of Neurology, Huashan Hospital Affiliated to Fudan University, Executive Deputy Director of Institute of Neurology, Fudan University, and Vice Chairman of the Youth Committee of Neurology Branch of Chinese Medical Association, highlighted the challenges of early Alzheimer's diagnosis, stressing the importance of early detection and intervention to mitigate disease progression. He clearly pointed out the main challenges of early diagnosis of AD and emphasized that once a patient enters the dementia stage, the existing treatments have limited effect, so early detection and intervention are crucial to slow down the progression of the disease. He pointed to the potential of plasma biomarker precision testing as a solution for large-scale diagnostic needs. Prof. Jintai Yu, of National Clinical Center for Neurological diseases in Shanghai, Deputy Director of Department of Neurology, Huashan Hospital Affiliated to Fudan University, Executive Deputy Director of Institute of Neurology, Fudan University, and Vice Chairman of the Youth Committee of Neurology Branch of Chinese Medical Association Meanwhile, Professor Yanning Cai, of National Clinical Center for Neurological Diseases in Beijing, Director of the Clinical Sample Center of Xuanwu Hospital of Capital Medical University in Beijing, and Deputy Director of the Key Project Department of the National Center for Neurological Diseases Medicine, Professor Cai Yanning focused on the importance of standardized clinical sample management, advocating for companies to establish comprehensive, standardized processes to ensure seamless clinical application of precision medicine. Professor Yanning Cai, of National Clinical Center for Neurological Diseases in Beijing, Director of the Clinical Sample Center of Xuanwu Hospital of Capital Medical University in Beijing, and Deputy Director of the Key Project Department of the National Center for Neurological Diseases Medicine Prof. Shukun Yao, PhD supervisor of Peking Union Medical College, Peking University, Beijing University of Traditional Chinese Medicine, former vice president of China-Japan Friendship Hospital, and Chief of Precision Medicine Specialized Committee, said after the academic discussion with Prof. Yu on the commonality, characteristics and differential diagnosis of AD and vascular dementia, "As the clinical side, we hope to join hands with scientific research and enterprises, and make concerted efforts from all sides, so as to contribute to the early diagnosis and early treatment of AD. " Prof. Shukun Yao, PhD supervisor of Peking Union Medical College, Peking University, Beijing University of Traditional Chinese Medicine, former vice president of China-Japan Friendship Hospital, and Chief of Precision Medicine Specialized Committee 【Important Voices】 Mr. Keith Crandell, Co-founder & Managing Director of ARCH, said, "We are very excited and confident about using Simoa for early diagnosis of AD and other diseases in China. We are fully committed to investing funds and resources to translate this breakthrough technology into products and solutions for research and diagnostics to help patients and their families around the world." Managing Director of GF Hong Kong Ms. Xiaoying Mai said, "We are excited about this technology and its potential, and are impressed with Jay Dong's passion, energy and leadership. GFHK fully supports this company that can provide a solution to the huge blue ocean market of early AD diagnosis and hopes that patients will soon benefit from this technology." "We believe that early detection is an important starting point for the treatment of disease. Many AD biomarkers in the blood are not detectable or cannot be detected earlier without the use of ultra-high sensitivity Simoa technology. Our collaboration with UltraDx Bio for IVD product development and commercialization in China will accelerate and improve early diagnosis of Alzheimer's disease patients." Dr. Masoud Toloue, CEO of Quanterix added, "We're excited about the IVD achievement, and a look forward to supporting UltraDX in broadening early Alzheimer's disease testing in China." "This is only a small step towards achieving a great mission: enabling early diagnosis and early intervention, and making our world a heathier planet", added passionately by Jay Dong, CEO of UltraDx. About Alzheimer's Disease Alzheimer's disease is the most common age-related neurodegenerative disorder, severely impacting patients and their families. China has the highest number of Alzheimer's patients globally, with over ten million affected individuals. By 2030, the economic burden associated with Alzheimer's in China is expected to reach nearly one trillion yuan. The Simoa®-based clinical tests developed by UltraDx Bio provide a new, efficient solution to this urgent need, enabling more accurate and early diagnosis for effective intervention and treatment. About UltraDx Bio Founded by scientist-entrepreneur Jay Dong, UltraDx Bio is recognized by leading biopharmaceutical venture capital funds, including ARCH and GF HK. The company's products leverage state-of-the-art Simoa® single-molecule array technology, adapted and approved for clinical use in China. With comprehensive capabilities in R&D, translational research, production, clinical registration, and quality management, UltraDx Bio focuses on developing diagnostic tools for neurological, infectious, immune, cardiovascular, and tumor diseases. The company operates R&D and production centers in Shanghai and Shijiazhuang, offering a robust product portfolio that includes AD early diagnostic instruments, reagents, and complete service solutions. By integrating leading global technology platforms with localized strategies and execution, UltraDx Bio is committed to advancing early disease diagnosis and improving human health. For more information, please contact us at info@ultradxbio.com.
HO CHI MINH, Vietnam, Sept. 5, 2024 /PRNewswire/ -- Saigon Ventures Co., Ltd. facilitated the signing of a Memorandum of Understanding (MOU) between South Korea's NEL Animal Medical Foundation (formerly NEL Animal Medical Center) and the Vietnam Small Animal Veterinary Association (VSAVA) to promote industry-academia collaboration and international exchange. (left - right) Nong Lam University, Professor, Minh Võ Dương, JS Services Trading Investment Co., Ltd., CEO, Lee Seung-ho, NEL Animal Medical Foundation, Chairman, Yun Il-yong, Vietnam Small Animal Veterinary Association, President, Lê Quang Thông, NEL Animal Medical Foundation, Director, Im Deok-ho, Son Sung-gi, Eom Tae-heum, Saigon Ventures Co., Ltd., CEO , Shin Hyun-kyu NEL Animal Medical Foundation is set to elevate pet care standards in Vietnam through its collaboration with PETPRO, one of the largest veterinary hospital chains in the country. Leveraging its world-class expertise in cardiac valve surgery and orthopedic neurosurgery, the foundation also aims to strengthen international veterinary exchange. In addition, an internship program will be established in partnership with HUTECH University's Faculty of Veterinary Medicine and other institutions, offering veterinary students the chance to gain global experience. This program will provide students with direct exposure to the foundation's cutting-edge medical technology and foster international collaboration. Under the banner of "Every pet deserves medical care," this collaboration will serve as a springboard for the international expansion of NEL Animal Medical Foundation's ESG initiatives. Key activities will include rescuing abandoned animals, providing international medical assistance, and conducting awareness campaigns. The progress of these efforts will be documented and shared through the Korean YouTube channel "You Said We Are Family". Im Deok-ho, Director of External Affairs at NEL Animal Medical Foundation, expressed his enthusiasm, stating, "I'm delighted that Korean veterinary medicine is gaining recognition and expanding its reach overseas, just like human medicine." He further added, "I hope this collaboration will foster greater international exchange in veterinary medicine and create opportunities to help abandoned pets in Vietnam." The consortium leading this collaboration includes Saigon Ventures Co., Ltd. and JS Services Trading Investment Co., Ltd. as Vietnamese partners. Social Links Instagram: https://www.instagram.com/nelamc24/ YouTube: https://youtube.com/channel/UCxtl0OOr3kBuZom7mzKmowQ?si=mLH6JC7y7dZt6ia facebook: https://www.facebook.com/nel24amf
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
